H.C. Wainwright Reiterates Buy Rating on VolitionRX (VNRX)

H.C. Wainwright analyst Yi Chen reiterated a Buy rating and $2.50 price target on VolitionRX (NYSE: VNRX).

The analyst commented: "Yesterday, VolitionRx announced that it had entered an agreement with Hologic Diagenode, a subsidiary of Hologic, for the co-marketing of Volition’s Nu.Q Discover service. Under the agreement, Hologic would co-market Nu.Q Discover services of Volition with Hologic customers for an initial term of one year. If successful, the aim is for Hologic to become an exclusive provider of those services, subject to further terms of agreement. Of note, Volition's Nu.Q Discover program enables drug developers and scientists access to a range of state-of-the-art assays for rapid epigenetic profiling in disease model development, preclinical testing, and clinical studies from discovery to being market ready. Hologic Diagenode is a leading provider in the field of epigenomics, with services designed to help advance biomarker discovery and validation by combining the strengths of epigenomics and bioinformatics. The incorporation of Nu.Q Discover biomarkers into a client's study design may help Hologic identify specific epigenetic signatures associated with disease states and treatment responses and in turn help advance the field of personalized medicine. In our view, this co-marketing agreement should expand the customer base for Volition’s Nu.Q Discover services. In the wake of this update, we reiterate our Buy rating and $2.50 price target."

For an analyst ratings summary and ratings history on VolitionRX click here. For more ratings news on VolitionRX click here.

Shares of VolitionRX closed at $0.62 yesterday.

You May Also Be Interested In

• J Capital Research cautious on Microchip: 'riding high on AI hype but looks weak'
• US crude oil inventories drop to lowest level since 1984
• Newmark hires ex-CBRE advisor to lead consulting group